Proinflammatory cytokine changes in clinically stable, virologically suppressed, HIV-infected patients switching from protease inhibitors to abacavir.
Virgili
Nuria
N
Fisac
Cesar
C
Martínez
Esteban
E
Ribera
Esteban
E
Gatell
Josep Maria
JM
Podzamczer
Daniel
D
D052242:Adiponectin / Q000097:blood; D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D048588:Benzoxazines / Q000008:administration & dosage / Q000627:therapeutic use*; D003521:Cyclopropanes; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019829:Nevirapine / Q000008:administration & dosage / Q000627:therapeutic use*; D047889:Receptors, Tumor Necrosis Factor, Type II / Q000097:blood; D000099227:Abacavir
D052242:Adiponectin; D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D015224:Dideoxynucleosides; D019829:Nevirapine; D047889:Receptors, Tumor Necrosis Factor, Type II; D000099227:Abacavir; C098320:efavirenz